Soligenix, Inc. (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medical need, announced today that it has enrolled and treated all patients in…
Source: First clinical study for development of SGX203 to treat pediatric Crohn’s disease
Monday, July 1, 2013
First clinical study for development of SGX203 to treat pediatric Crohn's disease
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment